Literature DB >> 32110195

Potential of Parameters of Iron Metabolism for the Diagnosis of Anemia of Inflammation in the Critically Ill.

Margit Boshuizen1,2, Jan M Binnekade1, Benjamin Nota3, Kirsten van de Groep4,5, Olaf L Cremer4, Janneke Horn1, Marcus J Schultz1,6, Robin van Bruggen2, Nicole P Juffermans1.   

Abstract

BACKGROUND: Anemia of inflammation (AI) is the most common cause of anemia in the critically ill, but its diagnosis is a challenge. New therapies specific to AI are in development, and they require accurate detection of AI. This study explores the potential of parameters of iron metabolism for the diagnosis of AI during an ICU stay.
METHODS: In a nested case-control study, 30 patients developing AI were matched to 60 controls. The iron parameters were determined in plasma samples during an ICU stay. Receiver operating characteristic curves were used to determine the iron parameter threshold with the highest sensitivity and specificity to predict AI. Likelihood ratios as well as positive and negative predictive values were calculated as well.
RESULTS: The sensitivity of iron parameters for diagnosing AI ranges between 62 and 76%, and the specificity between 57 and 72%. Iron and transferrin show the greatest area under the curve. Iron shows the highest sensitivity, and transferrin and transferrin saturation display the highest specificity. Hepcidin and ferritin show the lowest specificity. At an actual anemia prevalence of 53%, the diagnostic accuracy of iron, transferrin, and transferrin saturation was fair, with a positive predictive value between 71 and 73%. Combining iron, transferrin, transferrin saturation, hepcidin, and/or ferritin levels did not increase the accuracy of the AI diagnosis.
CONCLUSIONS: In this explorative study on the use of different parameters of iron metabolism for diagnosing AI during an ICU stay, low levels of commonly measured markers such as plasma iron, transferrin, and transferrin saturation have the highest sensitivity and specificity and outperform ferritin and hepcidin.
Copyright © 2019 by S. Karger AG, Basel.

Entities:  

Keywords:  Anemia of inflammation; Critically ill; Diagnosis; Iron; Transferrin

Year:  2019        PMID: 32110195      PMCID: PMC7036579          DOI: 10.1159/000497123

Source DB:  PubMed          Journal:  Transfus Med Hemother        ISSN: 1660-3796            Impact factor:   3.747


  23 in total

Review 1.  Case-control and two-gate designs in diagnostic accuracy studies.

Authors:  Anne W S Rutjes; Johannes B Reitsma; Jan P Vandenbroucke; Afina S Glas; Patrick M M Bossuyt
Journal:  Clin Chem       Date:  2005-06-16       Impact factor: 8.327

2.  Clinical practice guideline: red blood cell transfusion in adult trauma and critical care.

Authors:  Lena M Napolitano; Stanley Kurek; Fred A Luchette; Gary L Anderson; Michael R Bard; William Bromberg; William C Chiu; Mark D Cipolle; Keith D Clancy; Lawrence Diebel; William S Hoff; K Michael Hughes; Imtiaz Munshi; Donna Nayduch; Rovinder Sandhu; Jay A Yelon; Howard L Corwin; Philip S Barie; Samuel A Tisherman; Paul C Hebert
Journal:  J Trauma       Date:  2009-12

Review 3.  Anemia of inflammation.

Authors:  Elizabeta Nemeth; Tomas Ganz
Journal:  Hematol Oncol Clin North Am       Date:  2014-05-28       Impact factor: 3.722

4.  Effect of anticoagulants on multiplexed measurement of cytokine/chemokines in healthy subjects.

Authors:  Angélique Biancotto; Xingmin Feng; Marc Langweiler; Neal S Young; J Philip McCoy
Journal:  Cytokine       Date:  2012-06-15       Impact factor: 3.861

5.  Serum hepcidin-25 may replace the ferritin index in the Thomas plot in assessing iron status in anemic patients.

Authors:  C Thomas; U Kobold; S Balan; R Roeddiger; L Thomas
Journal:  Int J Lab Hematol       Date:  2010-09-27       Impact factor: 2.877

Review 6.  Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation.

Authors:  Tomas Ganz
Journal:  Blood       Date:  2003-03-27       Impact factor: 22.113

7.  The CRIT Study: Anemia and blood transfusion in the critically ill--current clinical practice in the United States.

Authors:  Howard L Corwin; Andrew Gettinger; Ronald G Pearl; Mitchell P Fink; Mitchell M Levy; Edward Abraham; Neil R MacIntyre; M Michael Shabot; Mei-Sheng Duh; Marc J Shapiro
Journal:  Crit Care Med       Date:  2004-01       Impact factor: 7.598

8.  Advantages of the nested case-control design in diagnostic research.

Authors:  Cornelis J Biesheuvel; Yvonne Vergouwe; Ruud Oudega; Arno W Hoes; Diederick E Grobbee; Karel G M Moons
Journal:  BMC Med Res Methodol       Date:  2008-07-21       Impact factor: 4.615

9.  Comparative evaluation of the effects of treatment with tocilizumab and TNF-α inhibitors on serum hepcidin, anemia response and disease activity in rheumatoid arthritis patients.

Authors:  Soken-Nakazawa J Song; Mitsuhiro Iwahashi; Naohisa Tomosugi; Kazuko Uno; Jiro Yamana; Seizou Yamana; Tomoyasu Isobe; Hiroki Ito; Hiroshi Kawabata; Kazuyuki Yoshizaki
Journal:  Arthritis Res Ther       Date:  2013-10-02       Impact factor: 5.156

10.  Effect of tocilizumab on haematological markers implicates interleukin-6 signalling in the anaemia of rheumatoid arthritis.

Authors:  John D Isaacs; Olivier Harari; Uwe Kobold; Janet S Lee; Corrado Bernasconi
Journal:  Arthritis Res Ther       Date:  2013       Impact factor: 5.156

View more
  1 in total

1.  Iron serum levels and iron homeostasis parameters in patients with nosocomial pneumonia treated with cefiderocol: post hoc analysis of the APEKS-NP study.

Authors:  Eric P Skaar; Roger Echols; Yuko Matsunaga; Anju Menon; Simon Portsmouth
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2022-01-13       Impact factor: 3.267

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.